Phase II Study of Letrozole (Femara) Plus Imatinib Mesylate (Gleevec) for Postmenopausal Patients With ER and/or PR Positive Metastatic Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Dec 2018
At a glance
- Drugs Imatinib (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 29 Nov 2018 Status changed from active, no longer recruiting to completed.
- 11 Oct 2018 Results published in the Investigational New Drugs
- 12 Sep 2018 Planned End Date changed from 1 Oct 2019 to 31 Oct 2019.